Earth Science Tech, Inc. (OTC: ETST) reported financial and operational results for the third fiscal quarter ended December 31, 2025, with revenue of $8.4 million, up 14.1% year over year. The company's gross profit reached $6.4 million, reflecting a 76.3% margin, while net income surged to $910,000, a 341% increase from the prior-year period. Adjusted EBITDA totaled $1.2 million, and total assets increased to $8.1 million.
Management attributed the strong performance to continued operating leverage and expansion initiatives. During the first nine months of fiscal 2026, the company repurchased and retired 3.7 million shares. The quarter ended with $416,000 in cash, $773,000 in working capital, and no bank debt.
Earth Science Tech operates as a strategic holding company focused on value creation through acquisition, operational optimization, and management of its operating businesses. Its current operations include compounding pharmaceuticals, telemedicine, and real estate development through wholly owned subsidiaries such as RxCompoundStore.com, LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC, Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC, and an 80% interest in MagneChef.
For more details, the full press release is available at https://ibn.fm/emIBm. The latest news and updates relating to ETST can be found in the company’s newsroom at https://ibn.fm/ETST.
The results underscore the company's ability to grow revenue and profitability while maintaining a strong balance sheet and returning value to shareholders through share repurchases. The significant improvement in net income, driven by higher revenue and improved margins, signals that Earth Science Tech's operational strategies are gaining traction. With no bank debt and positive working capital, the company is well-positioned to pursue further expansion in its core businesses.
These developments are particularly noteworthy for investors tracking small-cap growth companies in the healthcare and real estate sectors, as Earth Science Tech demonstrates that a diversified holding company model can deliver substantial earnings growth. The company's focus on compounding pharmaceuticals and telemedicine aligns with broader industry trends toward personalized medicine and remote healthcare services, which have seen increased demand.
